SecBot SecBot
PRESS-RELEASE ·Filed May 1, 2026

VXRT

Vaxart, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The substantial EPS miss and lack of revenue disclosure are bearish signals. Traders should monitor the upcoming Q1 2026 report on May 7 for any signs of revenue recovery or guidance.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.7700
T+0 close · May 1, 2026 · via day close
Latest settled
−37.66%
T+60 · $0.4800
Vs SPY
−40.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $0.7700entry
  2. T+1 · 7mo ago −1.30%α −0.96% · $0.7600
  3. T+5 · 6mo ago −3.90%α −6.24% · $0.7400
  4. T+20 · 6mo ago −18.18%α −23.47% · $0.6300
  5. T+60 · 4mo ago −37.66%α −40.73% · $0.4800

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart reported a significant Q4 2025 EPS miss of -$0.10 versus the $0.02 consensus, a 600% negative surprise. No revenue figure was provided in the filing, and the company has announced its Q1 2026 results will be reported on May 7, creating a period of uncertainty.

Key Financial Metrics

EPS
−$0.10
est $0.02 · -600.0%
Rating
strong miss

Key Facts

  • Q4 2025 EPS of -$0.10 missed the $0.02 consensus estimate by 600%.
  • No revenue figure was reported in this filing.
  • The company announced it will report Q1 2026 financial results on May 7.
  • Cross-filing actuarial verdicts indicate amplifiers for press-8k-context with press-activist-context and press-offering-context, suggesting heightened sensitivity to this earnings miss.

Financial Impact

EPS miss of -$0.10 vs $0.02 consensus, representing a 600% negative surprise.

eps

Risk Factors

  • Continued operational underperformance leading to further EPS misses.
  • Potential for negative revenue surprise when Q1 2026 results are released.
  • Low liquidity and high volatility typical of OTC-listed biotech stocks.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3285875

Track record

23 reports on VXRT

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 1, 2026